Agree Realty is an integrated real estate investment trust primarily focused on the ownership, acquisition, development and management of retail properties net leased to tenants. The company's assets are held by, and all of its operations are conducted through, directly or indirectly, Agree Limited Partnership, of which the company is the sole general partner and in which it holds a majority interest.

AMREP, through its subsidiaries, is engaged in the real estate business. The company conducts its real estate business primarily in the City of Rio Rancho and certain adjoining areas of Sandoval County, NM. The company sells both developed and undeveloped lots to national, regional and local homebuilders, commercial and industrial property developers and others. The company also acquires land, focusing primarily in New Mexico, after completion of market research, soil tests, environmental studies and other engineering work, a review of zoning and other governmental requirements, discussions with homebuilders or other end-users of the property and financial analysis of the project and estimated development costs.

Avid Biosciences is a contract development and manufacturing organization that provides a range of services from process development to Current Good Manufacturing Practices (CGMP) commercial manufacturing focused on biopharmaceutical products derived from mammalian cell culture. The company's services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company also provides a variety of process development services, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The company has product candidates in clinical and preclinical development to treat post-surgical ocular pain and inflammation, allergic conjunctivitis, dry eye disease, among other conditions. The company's drug application, DEXTENZA? (dexamethasone ophthalmic insert) 0.4mg is for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The company is also assessing the potential use of its hydrogel platform technology in other areas of the body.